News - CSL Behring


Current filters:

CSL Behring

Popular Filters

EMA approves fortnightly dosing option for CSL’s Hizentra

EMA approves fortnightly dosing option for CSL’s Hizentra


Plasma-protein specialists CSL Behring, a subsidiary of Australia’s CSL Ltd (CSL: AX), announced today…

CSL BehringEuropeHizentraImmunologicalsPharmaceuticalRegulationUK

CSL Behring’s Hizentra approved in Japan for PID and SID

CSL Behring’s Hizentra approved in Japan for PID and SID


The Japanese Ministry of Health, Labor and Welfare has approved Hizentra for the treatment of primary…

Asia-PacificCSL BehringHizentraImmunologicalsPharmaceuticalRare diseasesRegulation

US Senator seeks answers from drugmakers on providing required discounts


US Senator Charles Grassley has written to two drug companies on behalf of an Iowa hospital that is not…

CSL BehringExparelHematologyKcentraNeurologicalNorth AmericaPacira PharmaceuticalsPharmaceuticalPoliticsPricing

CSL Behring's rIX-FP shows efficacy in severe hemophilia B


Data presented by CSL Behring today (July 3) showed clinical efficacy of a once-weekly dosing regimen…

CSL BehringCSL LimitedPharmaceuticalResearch

CSL Behring's Berinert OKed in Europe for short-term prophylaxis in HAE


Germany-based CSL Behring, a unit of Australia's CSL Ltd (ASX: CSL) says that European health authorities…

BerinertBiotechnologyCSL BehringCSL LimitedEuropeRare diseasesRegulation

CSL Behring gains expanded use for Corifact in USA


Corifact, Factor XIII Concentrate (Human), to include the peri-operative management of surgical bleeding…

CorifactCSL BehringCSL LimitedNorth AmericaPharmaceuticalRare diseasesRegulation

CSL Behring enrolls first patient in pediatric Ph III pivotal study of rIX-FP to treat hemophilia B


USA-based CSL Behring, a subsidiary of Australia's CSL Ltd (ASX: CSL) has announced that the first patient…

BiotechnologyCSL BehringCSL LimitedResearchriX-FP

CSL Behring gets European OK for Hizentra


Germany-based CSL Behring says that the European Commission has granted marketing authorization for Hizentra…

CSL BehringCSL LimitedEuropeHizentraImmunologicalsPharmaceuticalRegulation

Back to top